Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer

Autor: D. M. Zahm, Jan Budczies, M K Mehta, E. Weiss, Manfred Dietel, S. Loibl, Ralf Kronenwett, Silvia Darb-Esfahani, Thomas Karn, M. Gehrmann, Hans Bojar, Carsten Denkert, F Khandan, Beyhan Ataseven, Achim Rody, Jan C. Brase, G. von Minckwitz
Rok vydání: 2012
Předmět:
Zdroj: British Journal of Cancer
ISSN: 1532-1827
0007-0920
DOI: 10.1038/bjc.2012.475
Popis: Background: Biomarkers predictive of pathological complete response (pCR) to neoadjuvant chemotherapy (NACT) of breast cancer are urgently needed. Methods: Using a training/validation approach for detection of predictive biomarkers in HER2-negative breast cancer, pre-therapeutic core biopsies from four independent cohorts were investigated: Gene array data were analysed in fresh frozen samples of two cohorts (n=86 and n=55). Quantitative reverse transcription polymerase chain reaction (qRT–PCR) was performed in formalin-fixed, paraffin-embedded (FFPE) samples from two neoadjuvant phase III trials (GeparTrio, n=212, and GeparQuattro, n=383). Results: A strong predictive capacity of thymosin beta 15 (TMSB15A) gene expression was evident in both fresh frozen cohorts (P
Databáze: OpenAIRE